创新双抗药物研发企业海徕科完成天使轮融资

Core Insights - Haileike has successfully completed its angel round financing, raising nearly 60 million yuan, led by Yuan Sheng Venture Capital and supported by several other investors [1][2] - The funds will primarily accelerate the preclinical research and Phase I clinical trials of its innovative antibody-cytokine fusion protein HL007, as well as the PCC screening and establishment of other pipelines [1][2] Group 1: Company Overview - Haileike, founded in 2022, focuses on developing next-generation bispecific and multispecific antibody drugs to address unmet clinical needs [2][9] - The company utilizes a mature and robust CADD design platform combined with various bispecific antibody formats to create innovative products [2][4] Group 2: Product Pipeline - The HL007 pipeline is designed to target cold tumors that are unresponsive to immunotherapy, utilizing PD-1 antibodies to enhance immune cell activity against tumor cells [3][6] - Other product pipelines are based on biological principles, offering differentiated solutions to clinical problems, showcasing high innovation potential [3] Group 3: Technology and Innovation - Haileike's CADD platform integrates AI technology for molecular modeling and docking, significantly improving the speed and success rate of antibody design compared to traditional methods [4] - The company has developed nearly 20 innovative products, most of which are advancing through various clinical stages [4] Group 4: Business Model and Strategy - Haileike employs a flexible business model, generating revenue through milestone payments and sales commissions from partnerships with domestic listed pharmaceutical companies [5] - The HL015 pipeline has been transferred to a domestic listed company, which has received clinical approval, indicating successful business development efforts [5] Group 5: Market Potential and Investor Confidence - Investors recognize the high therapeutic potential of bispecific and multispecific antibodies for treating tumors and autoimmune diseases, with major pharmaceutical companies actively investing in this area [8] - The HL007 pipeline has shown promising preclinical results, with better initial therapeutic effects and safety compared to competitors, positioning it as a potential blockbuster product [8]